Screener
CG Oncology CGON Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
| Assets | June 30, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $19,636 | $32,490 |
| Marketable securities | 1,008,642 | 709,665 |
| Inventory | 1,003 | 1,565 |
| Accounts receivable, net | 417 | 688 |
| Prepaid expenses and other current assets | 19,949 | 15,067 |
| Total current assets | 1,049,647 | 759,475 |
| Property and equipment, net | 14,707 | 15,596 |
Item 1. Financial Statements.
FAQ
- What is CG Oncology's short-term investments?
- CG Oncology (CGON) reported short-term investments of $1.01B in Q2 2026.
- How has CG Oncology's short-term investments changed year-over-year?
- CG Oncology's short-term investments increased by 56.0% year-over-year, from $646.43M to $1.01B.
- What is the long-term trend for CG Oncology's short-term investments?
- Over 2 years (2023 to 2025), CG Oncology's short-term investments has grown at a 98.9% compound annual growth rate (CAGR), from $179.41M to $709.67M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about CG Oncology's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude